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Dihydro-β-agarofuran sesquiterpenes from Celastraceae have been recently shown to bind to human P-glycoprotein (Pgp), functioning as
specific, mixed-type inhibitors of its drug transport activity, as well as multidrug resistance (MDR) modulators in vitro. However, nothing is
known about whether such compounds are themselves transported by Pgp, or whether they affect Pgp expression as well as its activity, or about
the location of their binding site within the protein. We performed transport experiments with a newly synthesized fluorescent sesquiterpene
derivative, which retains the anti-Pgp activity of its natural precursor. This probe was poorly transported by Pgp, MRP1, MRP2 and BCRP
transporters, compared with classical MDR substrates. Moreover, Pgp did not confer cross-resistance to the most potent dihydro-β-agarofurans,
which did not affect Pgp expression levels in several MDR cell lines. Finally, we observed competitive and non-competitive interactions between
one of such dihydro-β-agarofurans (Mama12) and classical Pgp modulators such as cyclosporin A, verapamil, progesterone, vinblastine and
GF120918. These findings suggest that multidrug ABC transporters do not confer resistance to dihydro-β-agarofurans and could not affect their
absorption and biodistribution in the body. Moreover, we mapped their binding site(s) within Pgp, which may prove useful for the rational design
of improved modulators based on the structure of dihydro-β-agarofurans.
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A considerable number of cancers are either intrinsically
resistant or exhibit treatment-induced acquired resistance,
which complicates efforts for the successful treatment of
cancer. Expression of P-glycoprotein MDR1 (Pgp) is among
the best documented mechanisms of MDR (multidrug resis-
tance) in human clinical cancers [1], and it has been detected in
virtually all tumour types in man at both diagnosis and during⁎ Corresponding author. Tel.: +34 958 181666; fax: +34 958 181633.
E-mail address: castanys@ipb.csic.es (S. Castanys).
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doi:10.1016/j.bbamem.2005.12.006relapse [2–4]. Moreover, expression of Pgp in many human
cancers correlates with response to therapy and survival [5–7].
The use of Pgp modulators has been suggested as a way to
overcome Pgp-mediated MDR [8] or even to prevent the
emergence of MDR in cancer patients [9]. Many agents that
modulate Pgp have been identified since the 1980s [10], but
most of them yielded disappointing results in vivo because they
were themselves transported by Pgp, competing with the
cytotoxic compounds being effluxed by the pump. Therefore,
they were too weak as Pgp inhibitors and very high serum levels
were necessary to achieve effective MDR reversion in patients,
resulting in unacceptable toxicity [11]. Moreover, many of these
chemosensitizers lack specificity, inhibiting also other ABC
transporters with well-defined physiological roles related to
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tics [12,13], leading to greater side effects of anticancer drugs
and resulting in unpredictable pharmacokinetic interactions that
preclude their clinical use. Therefore, a Pgp modulator for
potential clinical use must be sufficiently effective to inhibit Pgp
(must itself be non-transportable), must be devoid of intrinsic
toxicity, and highly specific for Pgp to avoid pharmacological
interactions with the co-administered anticancer drugs [14].
In our previous work, we demonstrated that dihydro-β-
agarofuran sesquiterpenes from Celastraceae family of plants
bind to transmembrane domains (TMDs) of human Pgp MDR1
(ABCB1), functioning as potent and specific mixed-competitive
inhibitors of its drug transport activity, with insignificant
inhibitory effects on the multidrug efflux pumps MRP1
(ABCC1), MRP2 (ABCC2) and BCRP (ABCG2) [15]. How-
ever, it remained to be determined if these natural products are
themselves transported by ABC multidrug efflux pumps, if they
alter Pgp expression levels as well as its activity, and besides, we
wanted to map their putative binding site within the Pgp TMDs.
For the former purpose, we have synthesized a new fluorescent
sesquiterpene derivative, which retains most of the MDR
reversal activity of its natural precursor. By using such a deri-
vative in transport studies, we have demonstrated in situ that
dihydro-β-agarofurans are either transported poorly or not at all
by Pgp or any other ABC transporter known to be involved in
cancer MDR. Furthermore, Pgp does not confer cross-resistance
to the most potent natural sesquiterpenes isolated in our lab
(Mama5, Mama12 and Machu4) [15], which supports the find-
ing described above. In addition, these natural sesquiterpenes do
not affect Pgp expression levels in a series of MDR cell lines.
Finally, we measured the effects of individual Pgp modulators
and pairs of modulators on the accumulation of daunorubicin
(DNM) in NIH-3T3MDR1 cells, and performed a simple kinetic
analysis that enables such data to be modelled in terms of com-
petitive, co-operative or non-competitive interaction between
pairs of modulators. Mama12, one of the most potent Pgp
sesquiterpene inhibitors described to date, seems to possess two
different binding sites, of high and low affinity, and at least oneFig. 1. Synthesis of the fluorescent derivative MANT-sesquiterpene. The synthesis w
of the natural sesquiterpene 1α-acetoxy-9α-benzoyloxy-8β,15-di(2-methylbutyroyloof them appears to interact competitively with that of cyclo-
sporin A and verapamil. Moreover, Mama12 does not bind to
vinblastine-binding site(s), or to progesterone-binding sites
[both in TMDs and in nucleotide binding domains (NBDs)].
Finally, Mama12 cooperates in a synergistic manner with
elacridar (GF120918) to bring about reversal of Pgp. The
information about the manner in which dihydro-β-agarofurans
bind to Pgp and interact with other Pgp substrates and
modulators could be of importance for the rational design of
new, improved Pgp inhibitors based on the molecular structure
of dihydro-β-agarofurans.
2. Materials and methods
2.1. Chemicals
Vinblastine (VNB), G418, adriamycin, vincristine, verapamil, cyclosporin A
(CsA), progesterone (PRG), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium], colchicine, N-methylisatoic anhydride (MIA), N-N-dimethylforma-
mide (DMF), and 4-dimethylaminopyridine (DMAP) were from Sigma-Aldrich.
[3H]-Azidopine (52 Ci/mmol) and NAMP100 amplifying solution for fluorog-
raphy were from Amersham Biosciences. Calcein-AM and Hoechst 33342 were
from Molecular Probes. GF120918 was from GlaxoSmithKline. The C219
monoclonal antibody, directed against Pgp, was fromCalbiochem. Daunorubicin
(DNM) was from Pfizer. Natural dihydro-β-agarofuran sesquiterpenes from
Celastraceae plants Mama5, Mama12 and Machu4 were isolated, purified and
characterized as described previously [16]. The sesquiterpene [1α-acetoxy-9α-
benzoyloxy-8β,15-di(2-methylbutyroyloxy)-2α,4β,6β-trihydroxydihydro-β-
agarofuran] from Crossopetalum tonduzi (sesquiterpene T3), described previ-
ously [17], was used for the synthesis of the 6β-methylanthranoyl (MANT)
fluorescent derivative (excitation/emission wavelength ∼350/446 nm) (Fig. 1).
2.2. Synthesis of MANT-sesquiterpene
In order to synthesize a fluorescent dihydro-β-agarofuran derivative active
as a Pgp modulator, the following considerations were taken into account: firstly,
the parental sesquiterpene should be itself active against Pgp and possess a free
hydroxyl group at position C-6 to allow the acylation of the molecule with the
chosen fluorescent probe. Secondly, the chosen fluorescent probe to be attached
at C-6 should resemble in size and chemical nature that of the typical groups that
occur in the basic scaffold of active natural sesquiterpenes. For these reasons,
sesquiterpene T3 and MIA were chosen as the parental molecule and the
fluorescent probe precursor, respectively.as achieved by regioselective acylation with MIA of the hydroxyl group at C-6β
xy)-2α,4β,6β-trihydroxydihydro-β-agarofuran (T3).
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mentioned natural dihydro-β-agarofuran sesquiterpene T3 was achieved by
regioselective acylation of the hydroxyl group at C-6β with MIA. Optical
rotations were measured on a Perkin-Elmer 241 automatic polarimeter, and the
[α]D are given in 10
−1 deg cm2 g−1. IR (film) spectra were recorded on a Bruker
IFS 55 spectrophotometer. 1H NMR and 13C NMR spectra were recorded on a
Bruker Avance 300 spectrometer. Electron impact mass spectroscopy (EIMS)
and high-resolution EIMS (HREIMS) were recorded on a Micromass Autospec
spectrometer. Monitoring and purification of the reactions were performed using
silica gel (TLC, plastic sheets, silica gel 60–250 UV250, Panreac).
MIA, DMF and DMAP were used without further purification. A solution of
sesquiterpene T3 (6.0 mg, 9.3×10−3 mmol), MIA (4 mg, 2.2×10−3 mmol) and
DMAP (0.2 mg, 1.6×10−3 mmol) in dry DMF (1.0 ml) was stirred for 18 h at
room temperature. The reaction was quenched by the addition of ethanol (0.5
ml) followed by stirring for 30 min at room temperature. The mixture was
evaporated with dryness, and the residue was purified by preparative TLC using
n-hexane/ethyl acetate (1:1), yielded 2.6 mg (36%) of the desired MANT-
sesquiterpene as a colourless lacquer, followed by 2.8 mg (47%) of the starting
material: [α]D
20=+40° (c 0.16, CHCl3); IR γmax (film) 3525, 3385, 2960, 2925,
2854, 1732, 1681, 1580, 1368, 1263, 1239, 1154, 1094, 1031, 755, 712 cm−1;
HNMR (CDCl3) δ 0.58 (3H, t, J=7.4 Hz), 0.87 (3H, d, J=7.0 Hz), 0.95 (3H, t,
J=7.4 Hz), 1.33 (3H, d, J=6.8 Hz), 1.38 (3H, s), 1.56 (3H, s), 1.64 (3H, s), 1.71
(3H, s), 1.82 (2H, m), 2.08 (2H, m), 2.21 (1H, m), 2.71 (1H, d, J=3.4 Hz), 2.77
(1H, m), 2.91 (3H, d, J=5.0 Hz), 4.16 (1H, d, J=2.7 Hz), 4.86, 5.06 (2H, dab,
J=13.4 Hz), 5.49 (1H, d, J=2.9 Hz), 5.84 (1H, dd, J=3.4, 9.8 Hz), 6.14 (1H, d,
J=9.8 Hz), 6.50 (1H, s), 6.63 (2H, m), 7.45 (3H, m), 7.57 (1H, d, J=7.6 Hz),
7.70 (1H, d, J=5.6 Hz), 7.94 (2H, dd, J=1.2, 8.3 Hz), 8.18 (1H, dd, J=1.4, 7.9
Hz); 13C NMR (CDCl3) δ 11.1 (q), 11.7 (q), 16.1 (q), 16.8 (q), 21.0 (q), 24.7 (q),
25.8 (q), 26. 2 (t), 26.6 (t), 29.5 (q), 31.9 (q), 41.1 (d), 41.6 (d), 44.3 (t), 51.7 (s),
52.1 (d), 62.1 (t), 67.5 (s), 69.9 (d), 73.8 (d), 75.6 (d), 84.0 (s), 78.1 (d), 92.2 (s),
109.5 (s), 110.7 (d), 114.9 (d), 128.6 (2x d), 129.6 (2x d, s), 132.7 (d), 133.4 (d),
135.0 (d), 152.0 (s), 165.9 (s), 167.2 (s), 169.7 (s), 175.2 (s), 176.3 (s); EIMS m/
z (%) 781 (M+, 0.5), 691 (1.0), 675 (0.7), 663 (0.5), 569 (0.7), 394 (1), 369 (0.8),
322 (2.9), 283 (0.6), 250 (1.1), 221 (2.0), 191 (1.2), 136 (14.7), 109 (20.1), 81
(37.5), 57 (100); HREIMS m/z calcd for C42H55N1O13 781.36734, found
781.36710.
2.3. Cell cultures
Mammalian cell lines were cultured at 37 °C in a humidified atmosphere
with 5% CO2, with their respective media supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine and 250 U/ml penicillin G plus 250 μg/ml
streptomycin sulphate (Invitrogen), as well as the appropriate concentration of
drugs indicated. The cell lines were: parental, drug-sensitive NIH-3T3 cells and
their MDR counterpart transfected with human MDR1-G185 (cultured in the
presence of colchicine 60 ng/ml) [18]; parental, drug-sensitive AuxB1 and the
MDR colchicine-selected lines CHRC5 (colchicine 10 μg/ml) [19], and CHRB30
(colchicine 30 μg/ml) [20]; parental, drug-sensitive MDCKII cells and their
MDR counterpart transfected with human MRP2 [21]; parental 2008 cells and
their MDR counterpart transfected with human MRP1 [22]; parental MDA-MB-
231 cells and their MDR counterpart transfected with human BCRP, MDA-MB-
231 BCRP clone F12 (G418 400 μg/ml), obtained in our laboratory by
subcloning of the original clone 23 [23] by the limit dilution method; parental,
drug-sensitive L1210S cells and the MDR L1210R (DNM 1 μM) [24]; parental
CCRF-CEM cells and the MDR sublines CCRF/ADR5000 (adriamycin 5 μg/
ml) and CCRF/VCR1000 (vincristine 1μg/ml) [25].
2.4. Cytotoxicity assays with sesquiterpenes and their influence on
Pgp expression
Intrinsic toxicity of sesquiterpenes in drug-sensitive cells and their Pgp-
expressing counterparts, as well as reversion of resistance to DNM and VNB,
were determined by the MTT colorimetric assay in 96 well-plates as described
[15]. Dose–response curves were generated by plotting percentage of cell
growth against concentration of cytotoxic drug (DNM or VNB), and the data
points (mean±S.D.; Pb0.05) were fitted by non-linear regression to a four
parameters logistic curve using SigmaPlot 2000 for Windows (SPSS Inc.) to
determine IC50 values and to calculate reversal indexes (ratio between IC50without and with modulator). The influence of sesquiterpenes Mama5,
Mama12 and Machu4 on Pgp expression was determined by measuring the
expression levels of the protein in CHRC5, CHRB30, L1210R, CCRF/
ADR5000 and CCRF/VCR1000 cells after 72 h incubation in the presence of
3 μM of each sesquiterpene. We checked first that such a concentration was
able to sensitize MDR cells by 60–90%, depending on the cell line, with low
intrinsic toxicity. After this incubation period, cells were harvested, washed
once with ice-cold PBS, diluted in ice-cooled hypotonic lysis buffer (10 mM
Tris–HCl pH 7.4 containing a cocktail of protease inhibitors; Sigma-Aldrich)
at a concentration of 1×106 cell/ml, and disrupted by 50 strokes in a teflon-
glass homogenizer, monitoring the disruption process under the microscope.
Then, the homogenates were centrifuged once at 500×g 4 °C to remove intact
cells and nuclei, and the supernatant submitted to ultracentrifugation
(100,000 × g 4 °C) to obtain the whole membrane and microsomal fraction.
The protein concentration in each sample was measured by the method of
Bradford, in order to process the same amount of total proteins of each
sample and allow reliable comparison of Pgp expression among different
samples. Proteins were resolved by SDS-PAGE on 9% gels and transferred to
PVDF membranes (Millipore), to perform Western blot for immunodetection
of Pgp using C219 monoclonal antibody.
2.5. MDR reversal and photoaffinity labeling assays with
MANT-sesquiterpene
In order to check the anti-Pgp activity of the newly synthesized fluorescent
sesquiterpene derivative, both the parental sesquiterpene (T3) and MANT-
sesquiterpene were studied in parallel as follows: MTT assays were performed
to test their respective abilities to reverse cellular resistance (as described
above), as well as flow cytometry analysis to test the inhibition of Pgp-
mediated DNM efflux in NIH-3T3 MDR1-G185 cells, as previously described
[15]. Measurement of the fluorescence signal of individual cells due to DNM
accumulation was performed with a Becton Dickinson FacScan. Moreover, in
order to demonstrate that the MANT-sesquiterpene binds to Pgp as do natural
sesquiterpenes, a competition assay of the photoaffinity labeling of Pgp by 3H-
azidopine was performed in the presence of a 100-fold molar excess of
MANT-sesquiterpene, as described in [26], using CHRB30 plasma membrane
vesicles purchased from the laboratory of Dr. Frances J. Sharom (Department
of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario,
Canada).
2.6. Accumulation and efflux experiments with MANT-sesquiterpene
Intracellular accumulation experiments with the MANT-sesquitepene were
performed by plating NIH-3T3 MDR1-G185, CHRC5, 2008-MRP1, MDCKII-
MRP2 or MDA-MB-231 BCRP clone F12 cells in 96-well plates (NUNC) at a
density of 2–4×104 cells/well. The following day, when cells were forming a
90% confluent monolayer in all the wells of a plate, the old medium was
removed and Pgp-, MRP1-, MRP2- and BCRP-expressing cells were incubated
at 37 °C in the presence of 10 μM MANT-sesquiterpene at increasing times
ranging from 0 to 180 min in order to generate time-dependent accumulation
curves. For comparison, similar curves were also generated for the different cell
lines in the presence of Pgp substrate DNM 10 μM (NIH-3T3 MDR1 and
CHRC5), 1 μM calcein-AM (2008-MRP1 and MDCKII-MRP2) or 1 μM
Hoechst 33342 (MDA-MB-231 BCRP clone F12). After each incubation period,
the monolayers were washed twice with cell culture medium plus 10% FBS in
order to remove any extracellular trace of fluorescent MDR substrate or MANT-
sesquiterpene. Finally, 50 μM of lysis buffer (Tris–HCl 20 mM pH 7.4, SDS
0.2%) were added to each well and incubated overnight at 4 °C in the dark. The
accumulated intracellular fluorescence due to DNM (λexcitation=480 nm;
λemission=590 nm), calcein (λexcitation=488 nm; λemission=520 nm), Hoechst
33342 or MANT-sesquiterpene (λexcitation=350 nm; λemission=446 nm) was
measured in a microplate spectrofluorometer “SpectraMax Gemini EM”
(Molecular Devices) using SoftmaxPro 4.3 software (also from Molecular
Devices).
Efflux experiments were performed as follows: cell monolayers in 96-well
plates were incubated for 2 h at 37 °C in the presence of 10 μM MANT-
sesquiterpene or DNM in order to load cells with each fluorophore. Afterwards,
the fluorophore-containing medium was removed, the monolayers were washed
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medium plus 10% FBS (to measure the intracellular retained fluorescence only)
or HPMI-glucose medium (to measure both intra and extracellular fluorescence),
both without fluorophore, were added to wells and incubated for different times
to allow the fluorophores to be effluxed out of cells. After different incubation
periods ranging from 0 to 90 min, the samples containing normal medium plus
10% FBS were submitted to another washing before adding the lysis buffer, in
order to remove extracellular fluorescence and to measure only the remaining
intracellular fluorescence. On the other hand, lysis buffer was added directly to
the samples containing HPMI-glucose medium without prior washing, and the
entire fluorescence signal was measured, i.e., the sum of both the intracellular
and the extracellular (effluxed) fluorescence. This control allowed us to rule out
the possibility of a decrease in intracellular fluorescence due to metabolic
degradation of the fluorescent probes, rather than active Pgp-mediated efflux
from the cells. After lysis of cell monolayers, the fluorescence was measured as
mentioned above and time-dependent efflux curves were generated with the
resulting data points.
2.7. Fluorescence microscopy
Cells incubated with 1 μM MANT-sesquiterpene for 2 h at 37 °C were
examined without previous fixation on a Zeiss Axiophot epifluorescence
microscope. Images were captured with a SPOT camera (Diagnostic
Instruments) and analysed using Adobe Photoshop 5.5 software.
2.8. Mapping of dihydro-β-agarofurans binding site within TMDs of
Pgp
The effects were measured of combinations of verapamil, VNB, CsA,
GF120918 (elacridar), PRG and natural sesquiterpene Mama12, used in pairs,
on the accumulation of DNM into NIH-3T3 MDR1 cells as described above:
cells plated in 96-well plates were exposed to 10 μM DNM in the absence/
presence of modulators. When present, each modulator was used at increasing
concentrations, either alone, or in combination with a different fixed con-
centration of a second modulator, in order to study how this second modulator
affected the behaviour of the first modulator as a blocker of Pgp-mediated DNM
efflux. Data analysis to establish the relationships among pairs of modulators
were performed as described by You-ming Shao and coworkers [27]. Briefly, the
authors used a simple kinetic analysis consisting in plotting the data of DNM
inhibition experiments and fitting such data points to hyperbolic curves
described by the equation
Di ¼ D0 þ ðDl  D0Þ  Ch=½Khi  ðDl=D0Þ þ Ch; ð1Þ
where Di is the amount of intracellular fluorescence due to DNM accumulation
in cells at any concentration of modulator C. D0 is DNM accumulation in the
absence of modulator, D∞ the accumulation at an infinitely high modulator
concentration, Ki is the intrinsic inhibition parameter of the reverser (i.e., the
concentration of modulator that produces 50% of DNM accumulation), and h is
the Hill coefficient that determines the sigmoidicity of the curve.
The parallel equation (Eq. (2)) describes the effects of pairs of modulators in
terms of the above variables and of the concentration of a second modulator B,
which acts as a competitive modulator of the first oneC. According to the classic
competition model of the enzymologists, we have
Di ¼ D0 þ ðDl  D0Þ  Ch=½Khi  ðDl=D0Þ  ð1þ BÞ þ Ch: ð2Þ
Therefore, the effect of a competitive second modulator is to increase the
apparent Ki of the first modulator by the factor (1+B), where B is the
concentration of the second modulator, divided by its intrinsic Ki. For the
case of a synergistic second modulator, i.e., one that interacts non-
competitively with the first modulator, the Eq. (1) remains unchanged.
Such a non-competitive modulator will not affect the Ki of the first modulator.
By fitting these equations to the data of Di against C, at any value of B, using
standard curve-fitting procedures, the appropriate values of Ki, D0 and D∞ can
be found. From the dependence of this computed value of Ki (which refers to
C) on the concentration of the second modulator B, one can test whether the
interaction between the two modulators is additive (when Ki will increase
with concentration of B) or synergistic (when Ki will remain unchanged). Inthe former case, one can find the appropriate value of Ki for the second
reverser.
Furthermore, the drop in the Hill number, found in some cases as one
increases the concentration of a second modulator, was used as a test for
distinguishing between true synergism (between non-competitors) and the type
of synergism displayed by two co-operating modulators, i.e., where the two
different modulators can replace each other at the binding site of Pgp. To further
support the above-described analysis, where necessary (see interaction between
PRG and Mama12), we also determined the type of Pgp inhibition caused by
pairs of modulators using the “Exploratory Enzyme Kinetics” application of the
SigmaPlot 2000 software for Windows, whose enzymological basis is the direct
linear plot [28]. By determining the type of interaction between sesquiterpene
Mama12 and other Pgp modulators, we were able to map the sesquiterpene-
binding site(s) of Pgp, and establish if that binding site is exclusive to
sesquiterpenes, or whether it is shared by different modulators along with
agarofurans.3. Results
3.1. MANT-sesquiterpene binds to and inhibits drug transport
activity of Pgp
The fluorescent derivative MANT-sesquiterpene should
retain the MDR reversal ability of its natural precursor if it is
intended to be a reliable probe for studying the mechanism of
action of dihydro-β-agarofurans as Pgp inhibitors. Consequent-
ly, we studied the MDR reversal activity and the ability to block
the Pgp-mediated DNM transport activity of both parental
sesquiterpene and MANT-sesquiterpene in NIH-3T3 cells over-
expressing human Pgp.
The ability of parental sesquiterpene (T3) (Fig. 1) and
MANT-sesquiterpene to reverse cellular MDR to DNM and
VNB in NIH-3T3 MDR1 cells was tested by MTT-based
cytotoxicity assays. IC50 for DNM were 30.3±11.3 and
383.0 ±62.1 ng/ml in drug-sensitive and MDR cells,
respectively (∼12.8-fold resistance). On the other hand,
IC50 for VNB in drug-sensitive and MDR cells were,
respectively, 1.3±0.6 and 121.0±24.3 ng/ml (∼93-fold
resistance). An important MDR reversion, comparable to that
caused by the classical modulator verapamil, was observed
when adding sesquiterpene T3 to the cell culture medium: when
reversing resistance to DNM, 3 and 10 μM T3 caused an IC50
shift in MDR cells from its original value (383.0±62.1 ng/ml)
to 118.2±24.1 and 19.8±6.3 ng/ml, respectively (3.2- and 19.3-
fold sensitization); on the other hand, when reversing VNB
resistance, 3 and 10 μM T3 shifted IC50 from 121.0±24.3 ng/
ml to 22.2±4.5 and 4.3±2.2 ng/ml, respectively (5.5- and 28.1-
fold sensitization).
Regarding MANT-sesquiterpene, despite its chemical mod-
ification with respect to the parental molecule, it was also able
to cause an important MDR reversion: at 3 and 10 μM, it was
able to produce, respectively, 3.6- and 10.4-fold sensitization to
DNM, and 1.9- and 12.3-fold sensitization to VNB. This means
that MANT-sesquiterpene retains a significant ability to reverse
MDR, only slightly affected by the MANT group.
In flow cytometry experiments, the fluorescence excitation
and emission spectra of MANT-sesquiterpene and DNM were
sufficiently different for fluorescence interference to exist
between the two fluorophores, which could affect the results
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results are shown in Fig. 2A, demonstrating that MANT-
sesquitepene inhibits DNM extrusion by Pgp with a potency
similar to that of parental sesquiterpene and that of the classical
modulator verapamil, at 1 and 10 μM.
Moreover, to confirm that MANT-sesquiterpene binds to
Pgp, as was previously demonstrated for natural sesquiterpenes
[15], we also performed competition assays of the photoaffinity
labeling of Pgp by 3H-azidopine in the presence of MANT-
sesquiterpene. The results are shown in Fig. 2B and suggest that
MANT-sesquiterpene may bind to TMDs of Pgp. Taken
together, these results seem to confirm that MANT-sesquiter-
pene is a reliable fluorescent derivative to study the mechanism
of action of natural sesquiterpenes as Pgp modulators since it
retains the activity and mode of action of its natural precursor.
3.2. Pgp does not confer cross-resistance to natural
dihydro-β-agarofuran sesquiterpenes because they are not
transport substrates of the pump
Using the MTT-based colorimetric cytotoxicity assay, we
determined the intrinsic toxicity of three natural sesquiterpenesFig. 2. MANT-sesquiterpene binds to and inhibits Pgp. The anti-Pgp activity of
the fluorescent derivative and its natural precursor was established by
modulation of DNM accumulation in NIH-3T3 MDR1, monitored by flow
cytometry (A). Verapamil was used as positive control of Pgp inhibition for
comparison. Results are the mean of two independent experiments, each
measurement performed in triplicate. In panel B the displacement is shown of
3H-azidopine binding to the Pgp drug binding-site, as determined by
photoaffinity labeling competition experiments. The result is representative of
two independent experiments. Upper: fluorography; Lower: immunodetection
of Pgp by Western blot using C-219 anti-Pgp monoclonal antibody.
Fig. 3. Cross-resistance to sesquiterpenes due to Pgp expression. Cytotoxicity
assays were performed to test the intrinsic toxicity of the three most potent
sesquiterpene inhibitors of Pgp available in our laboratory (Mama5, Mama12
and Machu4) against drug-sensitive and NIH-3T3 MDR1 cells. The plots
show representative experiments of three different ones, each performed in
triplicate.(Mama5, Mama12 and Machu4). Among those isolated in our
lab, these were the most potent compounds to reverse Pgp-
dependent MDR [15]. As shown in Fig. 3, none of them was
more toxic in drug-sensitive cells than in MDR cells, as would
be expected if Pgp conferred cross-resistance to them (i.e., if
they were Pgp transport substrates). Strikingly, these natural
sesquiterpenes were even slightly more toxic to Pgp-expressing
cells than to drug-sensitive cells.
Once we demonstrated that Pgp does not confer cross-
resistance to dihydro-β-agarofuran sesquiterpenes, we were
interested in demonstrating that the absence of cross-resistance
was due to the fact that sesquiterpenes are either poorly tran-
sported or not at all by human Pgp. In order to address this issue,
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experiments in Pgp-expressing intact cells. In the accumulation
experiments, NIH-3T3 wild-type and MDR1 cells were
incubated with either 10 μM MANT-sesquiterpene or 10 μM
DNM (a classical Pgp substrate) at increasing times in order to
generate time-dependent accumulation curves. As expected
(Fig. 4A), DNM readily accumulates in NIH-3T3 wild-type
cells but very scantly in MDR1 cells. However, MANT-
sesquiterpene (Fig. 4B) accumulates similarly in both cell
lines, regardless of Pgp expression. In order to rule out the
possibility to overwhelm the ability of Pgp to extrude MANT-
sesquiterpene, we repeated the same experiment at 10-fold
lower MANT-sesquiterpene concentration (1 μM). In this case,
only negligible differences (plots not shown) of MANT-
sesquiterpene accumulation were observed between Pgp-
expressing and non-expressing cells, similarly to the results
shown in Fig. 4A and B.
In efflux experiments, cells were incubated for 2 h with
either 10 μMDNM or 10 μMMANT-sesquiterpene. According
to the time-dependent accumulation curves described above,
2 h was sufficient to allow the fluorescent probes to reach
the maximal accumulation level within the cells. After this
incubation step, the fluorophore-containing medium was
removed, the cells washed, subsequently incubated in fluor-
ophore-free medium, and the remaining intracellular fluores-
cence was measured at increasing times. The rate of DNM
efflux increased greatly in those cells expressing Pgp at the
plasma membrane (Fig. 4C), but the rate of MANT-sesquiter-
pene efflux was almost unaffected (Fig. 4D). In order to rule out
the possibility that the decrease measured in fluorescence was
due to intracellular quenching or metabolization of the probes,
rather than active efflux, we performed parallel experiments, as
described above, measuring the whole fluorescence (intracel-
lular plus extracellular/effluxed) at increasing times, instead of
only the remaining intracellular fluorescence. It was observed
(data not shown) that both DNM and MANT-sesquiterpene
were not quenched intracellularly, but effluxed out of the cells
either by active pumping (in the case of DNM) or by passive
diffusion down the concentration gradient (in the case of
MANT-sesquiterpene).
Finally, to establish that the previous results were not cell-
specific but a general phenomenon resulting from sesquiter-
pene-Pgp interaction, the same experiments were performed in
another Pgp-expressing cell line. We chose the line CHRC5 due
to its high Pgp expression levels (up to 5% of total plasma
membrane proteins), which would allow us to determine
beyond a doubt whether MANT-sesquiterpene was transported
or not by the drug efflux pump. The results shown in Fig. 4E
and F (DNM and MANT-sesquiterpene, respectively) seem to
suggest that MANT-sesquiterpene, although far less than DNM,
was actively pumped out by Pgp since the probe accumulated
about 20% less in CHRC5 cells with respect to parental AuxB1
cells. In order to verify that such a finding was not due to
differences in the membrane permeability of MANT-sesquiter-
pene between the parental AuxB1 line and its MDR counterpart,
we also performed efflux experiments (Fig. 4G and H), which
demonstrated that MANT-sesquiterpene was indeed activelyeffluxed from Pgp-expressing CHRC5 cells, although very
poorly and far less efficiently than the classical Pgp substrate
DNM.
3.3. Intracellular localization of MANT-sesquiterpene in
NIH-3T3 cells by fluorescence microscopy
We have demonstrated that MANT-sesquiterpene was a very
poor Pgp substrate, whose time-dependent intracellular accu-
mulation was only affected by the drug efflux pump when it is
highly over-expressed. In NIH-3T3 MDR1 cells, Pgp expres-
sion levels do not reach such high levels, which would explain
that even at 1 μM MANT-sesquiterpene, the time-dependent
accumulation curves are essentially indistinguishable in both
wild-type and MDR1 cells. However, despite not being high
enough to affect the intracellular accumulation of MANT-
sesquiterpene, Pgp levels in NIH-3T3 cells may be sufficiently
high to affect the intracellular distribution pattern of the
fluorescent probe. In order to confirm the above, we analysed
samples of both cell lines (Pgp expressing and non-expressing
NIH-3T3 cells) by fluorescent microscopy after 2-h incubation
in the presence of 10 μM MANT-sesquiterpene. The cells were
not fixed after the incubation period to avoid any artifacts in the
distribution pattern of intracellular fluorescence. No significant
differences were found in the distribution pattern between both
cell lines: MANT-sesquiterpene enters the cells through the
plasma membrane by simple diffusion, and it spreads
throughout the entire cytoplasm in a scattered distribution,
concentrating mainly in the perinuclear region (possibly the
endoplasmic reticulum vesicles) but without staining the cell
nucleus (not shown).
3.4. Effect of natural dihydro-β-agarofuran sesquiterpenes on
Pgp expression
Previously, we have demonstrated that natural dihydro-β-
agarofuran sesquiterpenes bind to TMDs of Pgp and inhibit its
drug transport activity in a mixed-type fashion [15]. Moreover,
we are reporting in the present work that the pump transports a
fluorescent sesquiterpene derivative poorly and does not confer
cross-resistance to natural dihydro-β-agarofurans. However, it
remained to be determined whether these natural compounds, in
addition to inhibiting their activity, affect the expression levels
of the protein. In order to clarify the issue, we used a series of
murine, hamster and human MDR cells (L1210R, CHRC5,
CHRB30, CCRF/ADR5000 and CCRF/VCR1000), which
over-express Pgp as their major mechanism of multidrug
resistance. Each Pgp-expressing cell line was incubated for 3
days in the presence of 3 μM of each natural sesquiterpene
(Mama5, Mama12 or Machu4). This concentration was selected
for not causing growth inhibition greater than 10% on any of the
above cell lines but, however, for being able to reverse
resistance to DNM by 60–90% depending on the cell line.
Fig. 5 shows the comparative Pgp expression levels in each cell
line with/without sesquiterpenes. The protein concentration of
all the samples was accurately determined, and equal amounts
of each sample were processed in order to allow reliable
Fig. 4. MANT-sesquiterpene accumulation and efflux experiments in Pgp overexpressing cells. NIH-3T3 MDR1 and drug-sensitive NIH-3T3 cells, as well as AuxB1
and CHRC5 cells, were incubated with either MANT-sesquiterpene or DNM (10 μM), and the accumulated intracellular fluorescence was measured at increasing times.
In parallel experiments, the same cell lines were allowed to accumulate each fluorescent probe over 2 h, then washed and further incubated in probe-free medium; the
remaining intracellular fluorescence was then measured at increasing times after washing (efflux experiments). The right column of plots represents experiments
performed using MANT-sesquiterpene as a probe for Pgp-mediated transport, and the left one shows those experiments using DNM for comparison as a classical Pgp
substrate. Accumulation (A, B, E and F) and efflux experiments (C, D, G and H) were carried out using NIH-3T3 MDR1 cells (A, B, C and D) and CHRC5 cells (E, F,
G and H). Each plot is a representative experiment of two different ones, each performed in triplicate.
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Fig. 5. Influence of sesquiterpenes on Pgp expression. Pgp expression levels in
different MDR cell lines were determined by Western blot and subsequent
immunodetection of the multidrug transporter after 3 days' incubation of each
cell line with a subtoxic concentration (3 μM) of the three most potent anti-Pgp
sesquiterpenes described in our laboratory. After this incubation period, cells
were homogenated and the entire membrane fraction was recovered. The protein
concentration was accurately determined in each sample, and equal amounts of
membrane proteins were resolved in SDS-PAGE and processed as described in
Materials and methods.
Fig. 6. Duration of the reversal effect of sesquiterpenes. NIH-3T3 MDR1 cells
were incubated with sesquiterpene Machu4 10 μM for 2 h, and then the cells
were washed to eliminate any trace of extracellular sesquiterpene. Then, the
ability of the intracellularly accumulated Machu4 to block Pgp drug transport
activity was estimated by measuring the time-dependent accumulation of DNM
(10 μM) in the continuous presence/absence of Machu4, or at different times
after washing. The plot shows a representative experiment of two independent
DNM accumulation experiments, each performed in triplicate.
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expression levels was detected.
3.5. Duration of the reversal effect of natural sesquiterpenes in
NIH-3T3 MDR1 cells
The time-dependent curve of MANT-sesquiterpene efflux
from NIH-3T3 cells (Fig. 4D) showed that the probe, in the
initial stage of efflux, left the cells quite fast by simple diffusion
down the concentration gradient; however, after 1 h, the efflux
rate slowed down dramatically, and the intracellular concentra-
tion of the probe remained stable at levels 30–40% of the
original fluorescent signal, decreasing then only very slowly.
This suggested that sesquiterpenes exist inside the cells in two
forms, one that could be free in the cytoplasm and diffuses fast
from the cells (initial stage of rapid efflux), and another form
tightly bound to its intracellular target(s), or sequestered inside
vesicles (later stage of very slow efflux). This implies that
sesquiterpenes, until complete removal, may remain for a con-
siderable time inside the cells exerting their pharmacological
action as Pgp inhibitors. In order to test this assumption, we
incubated NIH-3T3 MDR1 cells with 10 μM of Machu4 (the
most potent sesquiterpene Pgp inhibitor) for 2 h, in order to load
cells with the natural sesquiterpene. Afterwards, cells were
washed and the ability of Pgp to actively extrude DNM was
tested in DNM accumulation experiments at increasing times
after washing the sesquiterpene from the cell culture medium. In
this situation, only the amount of sesquiterpene remaining
inside the cells could exert any measurable Pgp inhibition. As
controls, the DNM-extruding activity of Pgp was also
determined in the absence (100% Pgp activity) and in the
continuous presence (complete inhibition of Pgp activity) of 10
μM Machu4. Fig. 6 shows the time-dependent DNM accumu-
lation curves in the continuous presence, and absence of
Machu4, and after its removal from the cell culture medium. It is
clear that, after washing, the sesquiterpene is still able to blockthe Pgp-dependent DNM extrusion for a considerable time.
Plotting the DNM accumulation level at a fixed time (20 min)
against the time elapsed after Machu4 removal from the
extracellular medium (plot not shown), the half-life of Machu4
activity inside the cells was estimated to be around 30 h.
3.6. Ability of MRP1, MRP2 and BCRP to transport
MANT-sesquiterpene
In order to explore the putative role of other human MDR
efflux pumps as potential transporters of dihydro-β-agarofuran
sesquiterpenes, the same MANT-sesquiterpene accumulation
experiments performed in Pgp-expressing cells were also
performed in cells over-expressing human MRP1, MRP2 or
BCRP multidrug efflux pumps. MANT-sesquiterpene was also
used at 10 μM, similarly to experiments in Pgp-expressing cells,
and a well-known fluorescent substrate for MRP1, MRP2 and
BCRP was tested in parallel at a relevant concentration for
comparison to MANT-sesquiterpene. The results of this set of
experiments are shown in Fig. 7. The probe calcein-AM was
actively effluxed by both MRP1 and MRP2 pumps (Fig. 7A and
C), but MANT-sesquiterpene was not (Fig. 7B and D).
Similarly, Hoechst 33342 was effluxed as expected for a
BCRP substrate (Fig. 7E), but MANT-sesquiterpene was not
(Fig. 7F). Therefore, these results suggest that none of the major
human multidrug ABC transporters plays a significant role in
the active transport of natural dihydro-β-agarofuran
sesquiterpenes.
3.7. Synergistic and co-operative interactions between natural
sesquiterpenes and classical modulators to bring about Pgp
inhibition
Table 1 shows, on one side, the effects (observed as Ki and
Hill number variations) of fixed Mama12 concentrations
Fig. 7. Ability of MRP1, MRP2 and BCRP multidrug transporters to efflux MANT-sesquiterpene. Cell lines overexpressing the human multidrug transporters MRP1
(B), MRP2 (D) and BCRP (F), and their drug-sensitive parental counterparts, were incubated with 10 μM MANT-sesquiterpene. The accumulated fluorescence was
measured at increasing times. 1 μM calcein-AM for MRP1 (A) and MRP2 (C), or 1 μMHoechst 33342 for BCRP (E) were used as control probes for measuring drug
transport mediated by each of these multi-drug transporters.
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increasing concentrations of five different classical Pgp
modulators (verapamil, VNB, CsA, GF120918 and PRG). On
the other side of the table is shown, conversely, the effect of
increasing fixed concentration of the five classical modulators
mentioned earlier on Ki and the Hill number of sesquiterpene
Mama12 as a blocker of Pgp-dependent DNM efflux in intact
cells. The values of the Hill number and Ki for Pgp-mediated
DNM transport inhibition were computed from curves fitted to
the experimental data points accordingly to Eq. (1) or Eq. (2)
(see Materials and methods), depending on the case. These
values are expressed as means±S.E. (Pb0.001) of two different
experiments for each pair of modulators, performed in triplicate.The intrinsic Ki of verapamil decreases slightly with
increasing Mama12 concentrations, rendering the Hill number
unaffected. However, Ki of Mama12 increases in the presence
of increasing verapamil concentrations, and its Hill number
decreases. An explanation of this finding is that Mama12 could
have 2 different binding sites, of high and low affinity,
respectively, within Pgp that are not coupled allosterically,
since the Hill number for Mama12-mediated inhibition of Pgp
transport activity is not much higher than 1. The binding of
Mama12 to its high affinity binding site would decrease
verapamil Ki (non-competitive interaction), but the Mama12
low affinity-binding site and the verapamil-binding site could
interact physically (competitively), causing the Mama12 Hill
Table 1
Interactions between pairs of Pgp modulators when inhibiting Pgp-mediated
DNM transport in intact cells
2nd modulator μM Hill number Ki (μM)
Verapamil
Mama12 0 1.07±0.12 1.17±0.13
0.25 1.11±0.19 1.08±0.17
0.5 1.10±0.29 0.67±0.12
1 1.16±0.34 0.34±0.23
CsA
Mama12 0 1.49±0.19 0.645±0.031
0.125 1.43±0.22 0.708±0.071
0.25 1.36±0.24 0.750±0.128
0.5 1.19±0.12 0.891±0.093
VNB
Mama12 0 2.73±0.41 26.14±2.62
0.25 2.51±0.32 24.86±3.15
0.5 2.64±0.36 17.66±0.72
1 2.41±0.38 12.31±1.65
GF120918
Mama12 0 1.52±0.16 0.113±0.008
0.125 1.71±0.28 0.071±0.007
0.25 1.44±0.34 0.062±0.009
0.5 1.49±0.29 0.045±0.005
PRG
Mama12 0 2.22±0.24 41.73±7.88
0.25 2.15±0.14 37.64±2.42
0.5 2.39±0.22 27.76±1.83
1 2.30±0.33 15.61±2.76
Mama12
Verapamil 0 1.06±0.08 0.70±0.11
1 0.86±0.07 0.83±0.15
2 0.68±0.05 1.02±0.22
3 0.65±0.05 1.93±0.35
CsA 0 1.16±0.13 0.65±0.04
0.125 1.08±0.07 0.73±0.03
0.25 1.10±0.10 0.70±0.03
0.5 1.09±0.04 0.74±0.05
VNB 0 1.18±0.10 0.77±0.08
5 1.17±0.09 0.74±0.06
10 1.12±0.05 0.66±0.07
20 1.07±0.12 0.42±0.09
GF120918 0 1.25±0.13 0.76±0.06
0.062 1.23±0.23 0.70±0.08
0.125 1.17±0.19 0.47±0.02
0.25 1.27±0.14 0.23±0.07
PRG 0 1.28±0.12 0.96±0.07
10 1.32±0.18 2.13±0.38
20 1.91±0.30 1.46±0.18
30 2.42±0.37 1.36±0.19
It is shown how increasing fixed concentrations of a second modulator modify
the kinetic parameters of Pgp inhibition caused by a first modulator. By a simple
analysis of these data, it is possible to determine the type of interaction
(competitive, non-competitive, synergistic) that exist between a given pair of
Pgp modulators when combined to bring about Pgp inhibition.
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existence of two different sesquiterpene binding sites within
Pgp is further supported by the fact that sesquiterpenes
modulate Pgp ATPase activity in a biphasic way, stimulatingATPase at concentrations lower than 1 μM and then inhibiting it
at higher concentrations [15].
In turn, Mama12 competitively interacts with CsA since both
modulators mutually increase their respective Ki. However, the
Mama12 Hill number, affected by the presence of verapamil,
remains unaffected by CsA. This suggests that CsA and
verapamil, although interacting competitively, and also com-
petitively with respect to Mama12, do not interact with Mama12
in exactly the same way. It is possible that CsA, given its huge
molecular volume, overlaps with both the high- and low-affinity
Mama12-binding sites and affects them indistinctively, but
verapamil is able only to overlap with one binding site, pre-
sumably the low-affinity one.
Mama12 and VNB seem to interact synergistically (non-
competitively), collaborating with each other to bring about Pgp
inhibition, since they mutually cause a decrease in their res-
pective Ki values without significantly affecting their respective
Hill numbers. In the same way, Mama12 and GF120918 also
interact in a synergistic manner, mutually boosting their effects
as Pgp-mediated DNM transport inhibitors.
Regarding the pair of modulators PRG and Mama12, when
PRG acts as the second modulator, two different effects on
Mama12 kinetic parameters can be distinguished: at PRG
concentrations lower than 10 μM, Mama12 Ki increases and the
Hill number remains constant, but at higher PRG concentrations
(up to 30 μM), Mama12 Ki decreases and the Hill number
increases. This would suggest the existence of two different
PRG-binding sites of high and low affinity, each one interacting
with Mama12 binding in a different manner: on one hand, a
competitive interaction would take place between the high
affinity PRG-binding site and Mama12-binding site(s) and, on
the other hand, a non-competitive interaction between Mama12-
binding site(s) and the low affinity PRG-binding site. However,
much care should be taken when interpreting these results since
PRG is quite an unusual Pgp modulator. It is known that PRG
indeed possesses two different binding sites within Pgp, one of
high affinity located at the TMDs (affinity constant lower than
10 μM, as shown in [29]), and another of lower affinity located
at the NBDs, with an affinity constant around 18-53 μM,
depending on the tested steroid [30]. PRG, at high concentra-
tions, inhibits Pgp drug transport activity, but at concentrations
around 10 μM or lower, it has the unusual property among Pgp
modulators to be able to stimulate the Pgp-mediated transport of
those substrates that bind to either the H site (for Hoechst 33342
and colchicine) or to the R site (for rhodamine 123 and
anthracyclines) within the TMDs in a positive allosteric manner
[31]. DNM is an anthracycline and, hence, it is expected to bind
to the R site, and its transport to be stimulated accordingly by
PRG. We have indeed observed such DNM transport stimula-
tion by PRG (not shown), but at concentrations higher than 10
μM this stimulatory effect of PRG disappeared, and only its
inhibitory effect remained. The presence of Mama12 up to 1 μM
was unable to preclude this phenomenon of DNM transport
stimulation by PRG, suggesting that both PRG- and Mama12-
binding sites within TMDs are not overlapping physically, and
that the apparent increase in Mama12 Ki caused by PRG up to
10 μM (as shown in Table 1) is the consequence of the DNM
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range, rather than a competitive interaction between PRG and
Mama12. A more detailed kinetic analysis was performed of the
combination of PRG up to 10 μM (stimulating concentration
range) with different fixed concentrations of Mama12, by using
the “Exploratory Enzyme Kinetics” application of SigmaPlot
2000 software for Windows. This revealed, indeed, a mixed-
type interaction between both modulators, which argues against
physical interactions between their respective binding sites
within TMDs. On the other hand, the observed drop in Mama12
Ki caused by PRG concentrations higher than 10 μM should be
due to the fact that the binding of PRG to its low affinity-
binding site at the NBDs causes a conformational change, as
previously described [30]. Such a change should then transmit
to TMDs and modify the Mama12-binding site(s) in a sense that
increases their affinity for Mama12 and also the Hill number to
values significantly equal to 2, coupling both sites allosterically
to bring about Pgp inhibition.
In turn, fixed Mama12 concentrations, when combined with
increasing PRG concentrations over 10 μM (inhibitory range),
induces a decrease in PRG Ki without affecting its Hill number,
suggesting non-competitive interactions, as was also suggested
above. The Mama12-binding site(s) should not overlap with
PRG-binding site within NBDs since dihydro-β-agarofuran
sesquiterpenes do not interact physically with that Pgp domain
[15], which further supports the result discussed earlier.
Mama12 binding to TMDs produces a conformational change
in Pgp that, despite its little magnitude (as shown in [15]),
should transmit to the NBDs and cause the steroids-binding site
to increase its affinity for PRG.
4. Discussion
In our previous work [15], we demonstrated that natural
dihydro-β-agarofuran sesquiterpenes from Celastraceae were
able to reverse potently cellular MDR by blocking specifically
human Pgp as mixed-type inhibitors of its drug transport
activity. Moreover, we also showed that these natural
compounds did not affect the activity of MRP1, MRP2 and
BCRP, providing evidence of their specificity of action. In the
present work, by using a newly synthesized sesquiterpene
fluorescent derivative (MANT-sesquiterpene) that possesses the
anti-Pgp activity of its natural precursor, we have proceeded to
further characterize the molecular mechanism of action of
dihydro-β-agarofuran as Pgp-inhibitors, supporting the findings
of our previous work. We have demonstrated, first of all, that
Pgp does not confer cross-resistance to natural sesquiterpenes
and, secondly, that this multidrug efflux pump, compared to
classical Pgp substrates such as DNM, transports MANT-
sesquiterpene almost insignificantly. In fact, such net transport
mediated by Pgp across the plasma membrane is only apparent
in cells that highly over-express the transporter, and only when
the efflux of the probe, rather than its accumulation, is
measured. This new finding, firstly, supports our previous
finding that showed dihydro-β-agarofuran sesquiterpenes to be
potent Pgp inhibitors since it is well known that good Pgp
substrates are usually poor inhibitors and vice versa [32]. Andsecondly, it lessens the possibility that Pgp contributes
significantly to sesquiterpenes transport in vivo since no tissue
or tumour has been shown to over-express Pgp up to the levels
(5% of total membrane proteins) necessary to observe any
signal of net Pgp-mediated sesquiterpene transport. Moreover,
neither MRP1/MRP2 nor BCRP efflux pumps are able to
transport MANT-sesquiterpene across the plasma membrane.
Therefore, none of the ABC multidrug efflux pumps implicated
in cancer MDR may be considered to be a resistance factor
against natural sesquiterpenes and, presumably, they would also
be unable to affect their intestinal absorption and biodistribu-
tion. That is an additional requirement, along with potency and
specificity of action, which any ideal MDR modulator should
satisfy.
We have also observed that the intracellular distribution of
MANT-sesquiterpene is not only restricted to the plasma
membrane (the final destination of functional Pgp in the
majority of cells), but the probe is also able to get inside the
cells and spread intracellularly, giving a scattered pattern of
intracellular fluorescence that concentrates mainly on the
perinuclear region of the cytoplasm. This suggests that the
probe accumulates in membrane vesicles of Golgi and
endoplasmic reticulum (ER), and that natural sesquiterpenes
potentially inhibit the activity not only of Pgp at the plasma
membrane, but also the newly synthesized pump, at ER level and
vesicles of the secretory pathway, along its entire path towards
the plasma membrane. The fact that sesquiterpenes do not seem
to be inactivated by intracellular metabolism (not shown), and
the long half-life of its intracellular activity (up to 30 h) further
support its potential ability to inhibit efficiently Pgp for a long
time both at the plasma membrane and in intracellular
compartments. The reversal efficiency and duration of the
anti-Pgp activity of sesquiterpenes within cells would be of great
importance for the clinical reversion of MDR in tumours, due to
the fact that inhibition of Pgp activity in 100% of Pgp-expressing
cells would avoid the risk of selecting MDR clones that would
expand and repopulate those tumours that were initially
responsive to chemotherapy. Moreover, it has been observed
that Pgp, along with its drug transport-related role in MDR, also
seems to exert anti-apoptotic activities due to its ability to
modulate ceramide-mediated apoptosis. It is presumed that Pgp
is able to do so by translocating both sphingomyelin from the
inner to the outer leaflet of plasma membrane [33,34], and
glucosyl-ceramide [35] from the cytoplasm to the Golgi lumen
in human breast cancer cells [36] and acute myeloid leukemia
cells [37]. Moreover, it has also been shown that Pgp inhibits
FAS-induced caspase-8 activation in an ATP hydrolysis-
dependent fashion [38]. Therefore, the potential clinical use of
sesquiterpenes as inhibitors of Pgp activity would not only
consist in reversing classical MDR, but also in restoring
sensitivity to FAS- and ceramide-dependent apoptosis in those
malignancies in which Pgp plays a well-defined anti-apoptotic
role.
We have also shown, by using a battery of Pgp-over-
expressing cells, that none of the most potent natural ses-
quiterpenes is able to alter Pgp expression levels in long-term
incubations. The over-expression of Pgp in cancer cells exposed
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signals [39]. Since stress is able to trigger many cellular
responses simultaneously, it has been suggested that Pgp over-
expression is only a part of a concerted, more global stress-
induced response for cell survival, orchestrated by orphan
nuclear receptors [40,41]. The fact that natural sesquiterpenes
inhibit Pgp activity but do not induce its expression would
suggest, first, that they may not interfere with the mdr1
transcription, translation or protein folding process and,
second, that they may not interact with orphan nuclear
receptors. The latter assumption is of particular importance
since this presumed property, if verified, would imply that
natural sesquiterpenes behave as “clean” MDR reversers that
would not trigger global protective responses in cancers, such
as those involving changes in the expression of other stress
proteins also involved in MDR along with Pgp (glutathione-S-
transferase, cytochrome P450 enzymes, DNA-repairing
enzymes, etc.).
Finally, the kinetic analysis of the interactions between the
natural sesquiterpene Mama12 and classical Pgp modulators to
inhibit Pgp-dependent DNM transport confirmed the TMDs of
the pump as the location for dihydro-β-agarofurans binding site
(s) within the protein. In addition, this analysis also allowed us
to find examples of both competitive and non-competitive
interactions between Mama12 and classical modulators, which
were consistent with previous information about the way in
which classical modulators interact with one another in pairs to
produce inhibition of Pgp. In brief, Mama12 possesses two
binding sites within TMDs of high and low affinity, and at least
one of them overlaps with verapamil and CsA binding sites,
presumably sharing with them the so-called pharmacophore 1
described in [42]. Moreover, Mama12 interacts non-competi-
tively with both VNB (which occupies the so-called pharma-
cophore 2) and the PRG high and low affinity binding-sites. The
fact that Mama12 does not compete with VNB, which is
presumed to bind to the Pgp H and R sites for drug transport
[31], is in agreement with our previous results [15] that showed
Mama12 to be a mixed-type inhibitor of Pgp-mediated
tetramethylrosamine transport (a dye known to bind to the R
site). Finally, Mama12 interacts synergistically with GF120918
(elacridar), mutually increasing their respective potencies to
bring about Pgp inhibition.
In summary, all these findings suggest that dihydro-β-
agarofurans are a promising new family of Pgp inhibitors that
may be safely and usefully used in clinical practice. Moreover,
its privileged scaffold would allow the rational design of new
structures even more potent and specific for Pgp. All the
information that we have obtained about the molecular
mechanism of action of dihydro-β-agarofurans will help us on
such rational design and, in fact, future work in our laboratories
will focus on that task using QSAR-based approaches.
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